Galantamine

From WikiCover

Jump to: navigation, search

On August 30, 2007, Ranbaxy Laboratories announced that the company has received tentative approval from the U.S. Food and Drug Administration to manufacture and market Galantamine Hydrobromide Tablets, 4mg, 8mg, and 12mg. Galantamine is indicated for the treatment of mild to moderate dementia of the Alzheimer's type. Total annual market sales for Razadyne were $130.0 million.

Name (required):

Comment:

Retrieved from "http://www.wikicover.com/Galantamine"